Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?
Diabete Type 2

About this trial
This is an interventional treatment trial for Diabete Type 2
Eligibility Criteria
Inclusion Criteria:
- Type 2 male/female diabetic patients
- Age 20-70 years
- A1C less than 10.5%
Exclusion Criteria:
- Type 1 diabetes; HbA1c > 10.5%
- Pregnancy
- Chronic liver disease
- Elevated (more than twofold the upper limit of normal) ALT, AST and CPK.
- High bilirubin
- Albumin < 3.5 g/dl
- INR >1-2 Diabetic ketoacidosis
- Urinary tract infection (UTI)
- Pancreatitis < 6 months prior to enrolment
- Renal impairment (creatinine clearance ≤50 ml/min)
- Treatment with anti-obesity drugs or glucagon-like peptide-1 receptor agonists (GLP-1RAs) 3 months prior to enrolment
- Non-compliance with follow-up visits.
Sites / Locations
- University of Sadat City
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Sitagliptin 50 mg twice daily
Empagliflozin 12.5 twice daily
Sitagliptin 50 mg + empagliflozin 12.5 mg
Empagliflozin 12.5 + sitagliptin 50mg
sitagliptin 50 mg is added for 12 weeks to T2DM not controlled with diet, exercise and metformin with or without other oral antidiabetic drugs.
Empagliflozin 12.5 mg is added for 12 weeks to T2DM not controlled with diet, exercise and metformin with or without other oral antidiabetic drugs.
empagliflozin 12.5 mg is added to the patients with HbA1c 7-10 % of sitagliptin 50 mg group for another 12 weeks.
sitagliptin 50 mg is added to the patients with HbA1c 7-10 % of empagliflozin 12.5 mg group for another 12 weeks.